Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
김효진, 심효섭, 김루시아, 김태정, 권건영, 이건국,
소속 상세정보
김효진 ( Kim Hyo-Jin )
Seoul National University College of Medicine Department of Pathology
심효섭 ( Shim Hyo-Sup )
Yonsei University College of Medicine Department of Pathology
김루시아 ( Kim Lucia )
Inha University College of Medicine Department of Pathology
김태정 ( Kim Tae-Jung )
Catholic University College of Medicine Department of Pathology
권건영 ( Kwon Kun-Young )
Keimyung University Dongsan Medical Center Department of Pathology
이건국 ( Lee Geon-Kook )
National Cancer Center Department of Pathology
KMID : 0357920140480010001
Abstract
Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
키워드
Anaplastic lymphoma kinase; Gene rearrangement; Lung neoplasms; Guideline
원문 및 링크아웃 정보
등재저널 정보